Skip to main content

Table 3 Multivariate analyses of significant factors for various endpoints in the 749 patients with NPC

From: Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy

Variable Local failure Regional failure Distant failure Disease failure Death (any cause)
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
T stage (T2, T3, and T4 vs. T1) 1.956 (1.371–2.790) <0.001 1.243 (0.809–1.912) 0.321 1.556 (1.282–1.888) <0.001 1.589 (1.363–1.853) <0.001 1.583 (1.328–1.886) <0.001
N stage (N1, N2, and N3 vs. N0) 1.233 (0.833–1.723) 0.218 1.416 (0.928–2.160) 0.106 1.741 (1.485–2.041) <0.001 1.617 (1.415–1.847) <0.001 1.690 (1.455–1.964) <0.001
Age (>50 vs. ≤50 years) 1.011 (0.490–2.086) 0.976 1.005 (0.365–2.769) 0.992 1.530 (1.037–2.256) 0.032 1.896 (1.403–2.561) <0.001 2.482 (1.770–3.482) <0.001
Sex (female vs. male) 0.826 (0.378–1.802) 0.631 0.797 (0.266–2.386) 0.685 1.066 (0.689–1.649) 0.776 1.017 (0.713–1.450) 0.926 0.900 (0.587–1.379) 0.627
Histology (type II/III vs. type I) 1.930E4 (0.000–6.656E258) 0.974 2.104E4 (0.000–) 0.981 2.313E4 (0.000–4.202E155) 0.955 1.397 (0.194–10.043) 0.739 1.037 (0.144–7.480) 0.971
Chemotherapy (CCRT, induction with CCRT, and CCRT with adjuvant vs. none) 0.921 (0.705–1.202) 0.544 0.920 (0.629–1.345) 0.666 1.002 (0.870–1.155) 0.973 0.947 (0.840–1.068) 0.375 0.969 (0.847–1.108) 0.644
  1. HR hazard ratio, CI confidence interval, CCRT concurrent chemoradiotherapy